

AF-353

Catalog No: tcsc5061



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

865305-30-2

Formula:

$C_{14}H_{17}IN_4O_2$

Pathway:

Membrane Transporter/Ion Channel

Target:

P2X Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 32 mg/mL (79.96 mM)

Alternative Names:

Ro-4

Observed Molecular Weight:

400.21

Product Description


AF-353 is a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC₅₀= 8.0).

IC₅₀ value: pIC₅₀ = 8.0 (pIC₅₀, for P2X3)

Target: P2X3/P2X2/3 receptor

in vitro: AF-353 is a highly potent inhibitor of α,β -meATP-evoked intracellular calcium flux in cell lines expressing recombinant rat and human P2X3 and human P2X2/3 channels. AF-353 also blocks human P2X2/3 channel function with marginally reduced potency (pIC₅₀ = 7.3). [1]

in vivo: SCI rats has significantly higher frequencies for field potentials and NVC than NL rats. Intravesical ATP increases field potential frequency in control but not SCI rats, while systemic AF-353 significantly reduces this parameter in both groups. AF-353 also reduces the inter-contraction interval in control but not in SCI rats; however, the frequency of NVC in SCI rats was significantly reduced.[2]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!